ESOP13 May 2026, 01:25 pm
Cipla Grants Stock Options and ESARs
AI Summary
Cipla Ltd's Board of Directors approved the grant of stock options and employee stock appreciation rights (ESARs) under the Cipla Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. The board also approved the appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27 and Mr. Sushrut Kulkarni as President & Global Chief – Integrated Product Development. The decisions were made at the board meeting held on May 13, 2026.
Key Highlights
- Cipla grants 25,323 stock options under ESOS 2013-A with a ₹2 exercise price.
- Cipla grants 4,74,589 ESARs under ESAR 2021 with a ₹2 exercise price per equity share.
- M/s Joshi Apte & Associates appointed as Cost Auditors for FY 2026-27.
- Mr. Sushrut Kulkarni appointed as President & Global Chief – Integrated Product Development, effective May 18, 2026.
Price Impact
More from CIPLA